Cramer Says Right Now IBM Buzz Grows Amid Valuation Debate
IBM is attracting fresh investor attention as its AI infrastructure strategy gains traction. Arvind Krishna’s reshape...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesIBM is attracting fresh investor attention as its AI infrastructure strategy gains traction. Arvind Krishna’s reshape...
Two leading firms cut Microsoft price targets ahead of fiscal Q4, but both retain bullish ratings as Copilot and Azur...
Choosing the right investing platform can save time and money. This guide shows how to pick tools that align with you...
Apple and Nvidia sit at the pinnacle of market caps, but they play very different roles in investors’ portfolios. Thi...
A top analyst argues that broad tariffs act like a dirty tax, risking higher debt costs as the U.S. grapples with a $...
When a high-profile artist steps away for health, the financial ripple is real—not just for the performer, but for sp...
Navigating travel rewards can feel like navigating a maze. This guide breaks down credit card travel rewards program ...
As travel rebounds, premium demand is reshaping cruise stock dashboards. This deep dive explains why norwegian cruise...
Block reveals a sweeping AI-focused restructuring, trimming about 40% of its workforce and triggering a strong after-...
A federal appeals court rejects the DOJ's bid to delay the tariff refund program, speeding relief for millions of tax...
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Celink’s Ryan LaRose outlines how reverse mortgage servicing is shaped by scale pressures and growth limits, driven b...